marley

MCOA Subsidiary cDistro Signs Distribution Agreement with Silo Wellness and Marley One Functional Mushrooms 

Marijuana Company of America, Inc. (OTC: MCOA) ("the Company"), a diversified holding company with operations and investments throughout the cannabis industry, today announced that its new wholly owned subsidiary cDistro, has reached an agreement with Silo Wellness, Inc. (CSE: SILO) (OTC: SILFF) (FRA: 3K70) to distribute Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family.

Silo Wellness, a leading global psychedelics company, chose cDistro as one of its first distributors to launch Marley One, the first global functional and psychedelic mushroom consumer brand.

The initial product offering will include a range of functional mushroom tinctures, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. Silo has also announced that it intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics.

"We believe it is important to be a leader in providing access to newer product categories, and we are honored to distribute and provide access to Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family," said Ron Russo, cDistro's President. "The Marley family name is an iconic part of our history and we're thrilled to bring these exciting new products into our fast growing distribution portfolio. We have already commenced our marketing efforts to introduce and distribute Marley One, in collaboration with Silo Wellness and the Bob Marley Family. This distribution agreement and other new initiatives, epitomizes our growth and plans for continued growth and expansion." "This represents a new beginning for Marijuana Company of America as it begins its quest to diversify its product base and begin significant strides to become a proactive leader in the Cannabis industry," said Jesus Quintero, CEO of Marijuana Company of America, Inc.

Silo's CEO, Douglass Gordon, stated, "We are pleased to have chosen cDistro as one of our initial distributors and we expect that as our global functional mushroom brands continues to develop that we will become the world's first global functional and psychedelic mushroom brand, guided by a vision to help people achieve healthier lifestyle."

About Marijuana Company of America, Inc. (OTC: MCOA)

Marijuana Company of America is a diversified holding company with operations and investments throughout the cannabis industry. MCOA focuses on acquisitions, as well as sales and marketing efforts of its wholly owned subsidiaries cDistro and hempsmart™ premium brand of hemp-based CBD (legal cannabidiol) products.

About cDistro

cDistro (Retail Service / Wholesale Prices) distributes CBD brands, along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America.

Forward-Looking Statements  

This news release contains "forward-looking statements," which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as "anticipate," "seek," "intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other periodic reports filed from time to time with the Securities and Exchange Commission.

For more information, please visit www.marijuanacompanyofamerica.com or visit www.sec.gov.

Contact
info@marijuanacompanyofamerica.com  
  info@mcoainvestments.com  
888-777-4362


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Participants received a single dose of either 25 mg of COMP360 or placebo
  • On track for disclosure of top-line 6-week primary endpoint results in late June

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Screening closed for all sites and final participants being scheduled for dosing
  • On track for top-line 6-week primary endpoint results in late Q2

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroup
  • Findings published in the March edition of the Journal of Clinical Psychiatry

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways to Participate in Stifel Virtual CNS Forum

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45 th Annual Health Care Conference at 1:10 pm ET on March 3 rd , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×